{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T20:21:33Z","timestamp":1778876493537,"version":"3.51.4"},"reference-count":35,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Vaccine Immunol"],"published-print":{"date-parts":[[2010,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>The biological threat imposed by orthopoxviruses warrants the development of safe and effective vaccines. We developed a candidate orthopoxvirus DNA-based vaccine, termed 4pox, which targets four viral structural components, A33, B5, A27, and L1. While this vaccine protects mice and nonhuman primates from lethal infections, we are interested in further enhancing its potency. One approach to enhance potency is to include additional orthopoxvirus immunogens. Here, we investigated whether vaccination with the vaccinia virus (VACV) interferon (IFN)-binding molecule (IBM) could protect BALB\/c mice against lethal VACV challenge. We found that vaccination with this molecule failed to significantly protect mice from VACV when delivered alone. IBM modestly augmented protection when delivered together with the 4pox vaccine. All animals receiving the 4pox vaccine plus IBM lived, whereas only 70% of those receiving a single dose of 4pox vaccine survived. Mapping studies using truncated mutants revealed that vaccine-generated antibodies spanned the immunoglobulin superfamily domains 1 and 2 and, to a lesser extent, 3 of the IBM. These antibodies inhibited IBM cell binding and IFN neutralization activity, indicating that they were functionally active. This study shows that DNA vaccination with the VACV IBM results in a robust immune response but that this response does not significantly enhance protection in a high-dose challenge model.<\/jats:p>","DOI":"10.1128\/cvi.00235-10","type":"journal-article","created":{"date-parts":[[2010,9,16]],"date-time":"2010-09-16T02:11:45Z","timestamp":1284603105000},"page":"1656-1665","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":6,"title":["Evaluating the Orthopoxvirus Type I Interferon-Binding Molecule as a Vaccine Target in the Vaccinia Virus Intranasal Murine Challenge Model"],"prefix":"10.1128","volume":"17","author":[{"given":"Joseph W.","family":"Golden","sequence":"first","affiliation":[{"name":"Department of Molecular Virology, Virology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland 21702"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay W.","family":"Hooper","sequence":"additional","affiliation":[{"name":"Department of Molecular Virology, Virology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland 21702"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1099\/vir.0.008474-0","volume":"90","year":"2009","unstructured":"Adamo, J. E., C. A. Meseda, J. P. Weir, and M. J. Merchlinsky. 2009. Smallpox vaccines induce antibodies to the immunomodulatory, secreted vaccinia virus complement control protein. J. Gen. Virol.90:2604-2608.","journal-title":"J. Gen. Virol."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.74.23.11230-11239.2000"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00621-10"},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0166-3542(03)00008-1","volume":"58","year":"2003","unstructured":"Bray, M. 2003. Pathogenesis and potential antiviral therapy of complications of smallpox vaccination. Antiviral Res.58:101-114.","journal-title":"Antiviral Res."},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"15974","DOI":"10.1074\/jbc.270.27.15974","volume":"270","year":"1995","unstructured":"Colamonici, O. R., P. Domanski, S. M. Sweitzer, A. Larner, and R. M. Buller. 1995. Vaccinia virus B18R gene encodes a type I interferon-binding protein that blocks interferon alpha transmembrane signaling. J. Biol. Chem.270:15974-15978.","journal-title":"J. Biol. Chem."},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.18.11724-11733.2005"},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1096\/fj.09-144733","volume":"24","year":"2010","unstructured":"Del Mar Fernandez de Marco, M., A. Alejo, P. Hudson, I. K. Damon, and A. Alcami. 2010. The highly virulent variola and monkeypox viruses express secreted inhibitors of type I interferon. FASEB J.24:1479-1488.","journal-title":"FASEB J."},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.virol.2005.09.056","volume":"345","year":"2006","unstructured":"Fang, M., H. Cheng, Z. Dai, Z. Bu, and L. J. Sigal. 2006. Immunization with a single extracellular enveloped virus protein produced in bacteria provides partial protection from a lethal orthopoxvirus infection in a natural host. Virology345:231-243.","journal-title":"Virology"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.19.10230-10237.2004"},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1006\/viro.1998.9516","volume":"254","year":"1999","unstructured":"Galmiche, M. C., J. Goenaga, R. Wittek, and L. Rindisbacher. 1999. Neutralizing and protective antibodies directed against vaccinia virus envelope antigens. Virology254:71-80.","journal-title":"Virology"},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.virol.2008.04.003","volume":"377","year":"2008","unstructured":"Golden, J. W., and J. W. Hooper. 2008. Heterogeneity in the A33 protein impacts the cross-protective efficacy of a candidate smallpox DNA vaccine. Virology377:19-29.","journal-title":"Virology"},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1016\/j.vaccine.2008.04.017","volume":"26","year":"2008","unstructured":"Golden, J. W., M. D. Josleyn, and J. W. Hooper. 2008. Targeting the vaccinia virus L1 protein to the cell surface enhances production of neutralizing antibodies. Vaccine26:3507-3515.","journal-title":"Vaccine"},{"key":"e_1_3_2_14_2","first-page":"421","year":"1985","unstructured":"Hashizume, S., H. Yoshizawa, M. Morita, and K. Suzuki. 1985. Properties of attenuated mutant of vaccinia virus, LC16m8, derived from Lister strain, p. 421-428. In G. V. Quainnan (ed.), Vaccinia viruses as vectors for vaccine antigens. Elsevier Science Publishing Co, Amsterdam, Netherlands.","journal-title":"Vaccinia viruses as vectors for vaccine antigens"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.4049\/jimmunol.177.4.2552","volume":"177","year":"2006","unstructured":"Heraud, J. M., Y. Edghill-Smith, V. Ayala, I. Kalisz, J. Parrino, V. S. Kalyanaraman, J. Manischewitz, L. R. King, A. Hryniewicz, C. J. Trindade, M. Hassett, W. P. Tsai, D. Venzon, A. Nalca, M. Vaccari, P. Silvera, M. Bray, B. S. Graham, H. Golding, J. W. Hooper, and G. Franchini. 2006. Subunit recombinant vaccine protects against monkeypox. J. Immunol.177:2552-2564.","journal-title":"J. Immunol."},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1006\/viro.1999.0096","volume":"266","year":"2000","unstructured":"Hooper, J. W., D. M. Custer, C. S. Schmaljohn, and A. L. Schmaljohn. 2000. DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge. Virology266:329-339.","journal-title":"Virology"},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0042-6822(02)00038-7","volume":"306","year":"2003","unstructured":"Hooper, J. W., D. M. Custer, and E. Thompson. 2003. Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates. Virology306:181-195.","journal-title":"Virology"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.09.133"},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1016\/j.vaccine.2006.11.017","volume":"25","year":"2007","unstructured":"Hooper, J. W., J. W. Golden, A. M. Ferro, and A. D. King. 2007. Smallpox DNA vaccine delivered by novel skin electroporation device protects mice against intranasal poxvirus challenge. Vaccine25:1814-1823.","journal-title":"Vaccine"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.9.4433-4443.2004"},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"7009","DOI":"10.1016\/j.vaccine.2006.03.087","volume":"24","year":"2006","unstructured":"Kenner, J., F. Cameron, C. Empig, D. V. Jobes, and M. Gurwith. 2006. LC16m8: an attenuated smallpox vaccine. Vaccine24:7009-7022.","journal-title":"Vaccine"},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1045-1870(03)00032-3","volume":"14","year":"2003","unstructured":"Lane, J. M., and J. Goldstein. 2003. Adverse events occurring after smallpox vaccination. Semin. Pediatr. Infect. Dis.14:189-195.","journal-title":"Semin. Pediatr. Infect. Dis."},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1007\/s00424-002-0862-5","volume":"444","year":"2002","unstructured":"Lauritzen, H. P., C. Reynet, P. Schjerling, E. Ralston, S. Thomas, H. Galbo, and T. Ploug. 2002. Gene gun bombardment-mediated expression and translocation of EGFP-tagged GLUT4 in skeletal muscle fibres in vivo. Pflugers Arch.444:710-721.","journal-title":"Pflugers Arch."},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1086\/421266","volume":"38","year":"2004","unstructured":"McCurdy, L. H., B. D. Larkin, J. E. Martin, and B. S. Graham. 2004. Modified vaccinia Ankara: potential as an alternative smallpox vaccine. Clin. Infect. Dis.38:1749-1753.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.22.12471-12479.2004"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.18.11873-11891.2005"},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0966-842X(00)01838-2","volume":"8","year":"2000","unstructured":"Moss, B., J. L. Shisler, Y. Xiang, and T. G. Senkevich. 2000. Immune-defense molecules of molluscum contagiosum virus, a human poxvirus. Trends Microbiol.8:473-477.","journal-title":"Trends Microbiol."},{"key":"e_1_3_2_28_2","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/bit.22312","volume":"103","year":"2009","unstructured":"Nguyen, D. N., P. Kim, L. Martinez-Sobrido, B. Beitzel, A. Garcia-Sastre, R. Langer, and D. G. Anderson. 2009. A novel high-throughput cell-based method for integrated quantification of type I interferons and in vitro screening of immunostimulatory RNA drug delivery. Biotechnol. Bioeng.103:664-675.","journal-title":"Biotechnol. Bioeng."},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00131-10"},{"key":"e_1_3_2_30_2","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.virol.2006.07.017","volume":"355","year":"2006","unstructured":"Sakhatskyy, P., S. Wang, T. H. Chou, and S. Lu. 2006. Immunogenicity and protection efficacy of monovalent and polyvalent poxvirus vaccines that include the D8 antigen. Virology355:164-174.","journal-title":"Virology"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.71.12.9563-9569.1997"},{"key":"e_1_3_2_32_2","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1146\/annurev.immunol.21.120601.141049","volume":"21","year":"2003","unstructured":"Seet, B. T., J. B. Johnston, C. R. Brunetti, J. W. Barrett, H. Everett, C. Cameron, J. Sypula, S. H. Nazarian, A. Lucas, and G. McFadden. 2003. Poxviruses and immune evasion. Annu. Rev. Immunol.21:377-423.","journal-title":"Annu. Rev. Immunol."},{"key":"e_1_3_2_33_2","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/0092-8674(95)90076-4","volume":"81","year":"1995","unstructured":"Symons, J. A., A. Alcami, and G. L. Smith. 1995. Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity. Cell81:551-560.","journal-title":"Cell"},{"key":"e_1_3_2_34_2","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.bbapap.2007.08.001","volume":"1784","year":"2008","unstructured":"Werden, S. J., and G. McFadden. 2008. The role of cell signaling in poxvirus tropism: the case of the M-T5 host range protein of myxoma virus. Biochim. Biophys. Acta1784:228-237.","journal-title":"Biochim. Biophys. Acta"},{"key":"e_1_3_2_35_2","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.vaccine.2006.10.009","volume":"25","year":"2007","unstructured":"Xiao, Y., L. Aldaz-Carroll, A. M. Ortiz, J. C. Whitbeck, E. Alexander, H. Lou, H. L. Davis, T. J. Braciale, R. J. Eisenberg, G. H. Cohen, and S. N. Isaacs. 2007. A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost. Vaccine25:1214-1224.","journal-title":"Vaccine"},{"key":"e_1_3_2_36_2","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1084\/jem.20071854","volume":"205","year":"2008","unstructured":"Xu, R. H., M. Cohen, Y. Tang, E. Lazear, J. C. Whitbeck, R. J. Eisenberg, G. H. Cohen, and L. J. Sigal. 2008. The orthopoxvirus type I IFN binding protein is essential for virulence and an effective target for vaccination. J. Exp. Med.205:981-992.","journal-title":"J. Exp. Med."}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00235-10","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00235-10","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T20:42:26Z","timestamp":1627591346000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00235-10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["10.1128\/CVI.00235-10"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00235-10","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11]]},"assertion":[{"value":"2010-06-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-08-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}